Senseonics (NYSE:SENS) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Stock Performance

NYSE:SENS opened at $0.35 on Friday. The business has a fifty day moving average of $0.39 and a 200-day moving average of $0.44. The stock has a market cap of $185.44 million, a price-to-earnings ratio of -2.50 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11. Senseonics has a 1 year low of $0.32 and a 1 year high of $0.75.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Equities analysts predict that Senseonics will post -0.13 earnings per share for the current year.

Institutional Trading of Senseonics

Several hedge funds and other institutional investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System purchased a new position in Senseonics in the first quarter valued at about $91,000. Virtu Financial LLC acquired a new stake in shares of Senseonics during the 1st quarter valued at about $162,000. Price T Rowe Associates Inc. MD grew its stake in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after acquiring an additional 211,128 shares in the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.